View printer-friendly version
« Back
July 19, 2005 11:33 a.m.
Teva Announces Record Global In-Market Copaxone® Sales of $291 Million in The Second Quarter, an Increase of 29%

Sales in The Last 12 Months Crossed The 1 Billion Dollar Mark

Jerusalem, Israel, July 19, 2005 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today, in conjunction with the release of the Sanofi-Aventis group's financial results, that global in-market sales of Copaxone® reached record $291 million in the second quarter of 2005, an increase of 29% over the comparable quarter of 2004.

U.S. sales in the second quarter 2005 increased 29% over the second quarter 2004 to $193 million. According to IMS, Copaxone® continued to hold its position as the market leader in both total and new prescriptions, reaching a TRx share of 32.7% in June 2005. Furthermore, based on IMS weekly prescription data, Copaxone® continued to be the leader in the last 10 and 19 weeks for TRx and NRx, respectively.

For the second quarter 2005, sales outside the U.S., mainly in Europe, increased by 28% over the comparable quarter of 2004, to $97 million.

Israel Makov, President and CEO of Teva commented: "We are very pleased by the excellent growth displayed by Copaxone in the second quarter. These record sales are a reflection of Copaxone's unmatched long term efficacy and its unique ability to address both the inflammatory and neurodegenerative aspects of MS. These attributes are no doubt the major driver in Copaxone®'s continuous global growth and leadership in the US."

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies and among the largest generic pharmaceutical companies in the world. The company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients. Close to 90% of Teva's sales are in North America and Europe. Teva's innovative R&D focuses on developing novel drugs for diseases of the central nervous system.



Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on management's current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause Teva's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include Teva's ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competitive generic products, the impact of competition from brand-name companies that sell or license their own generic products (so called "authorized generics") or successfully extend the exclusivity period of their branded products, the effects of competition on Copaxone® sales, including potential competition from the expected launch of Tysabri®/Antegren®, Teva's ability to rapidly integrate the operations of acquired businesses, including its acquisition of Sicor Inc., regulatory changes that may prevent Teva from exploiting exclusivity periods, potential liability for sales of generic products prior to completion of appellate litigation, including that relating to Neurontin, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Association and other regulatory authority approvals, the regulatory environment and changes in the health policies and structure of various countries, Teva's ability to successfully identify, consummate and integrate acquisitions, exposure to product liability claims, dependence on patent and other protections for innovative products, significant operations outside the United States that may be adversely affected by terrorism or major hostilities, fluctuations in currency, exchange and interest rates, operating results and other factors that are discussed in Teva's Annual Report on Form 20-F and its other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.